Savara Investors Face Nov. 7 Lead‑Plaintiff Deadline in Securities Suit Over FDA Refusal‑to‑File

Overview

• Multiple law firms are urging Savara shareholders to seek lead‑plaintiff appointment by November 7, 2025 in a federal securities class action.
• Notices largely define the class period as March 7, 2024 through May 23, 2025, while Levi & Korsinsky lists a March 4, 2024 start date.
• The complaints allege Savara misled investors about the completeness and timing of the MOLBREEVI BLA and the likelihood of needing additional capital.
• Savara disclosed on May 27, 2025 that the FDA issued a refusal‑to‑file for the MOLBREEVI BLA, requesting more Chemistry, Manufacturing, and Controls data.
• Following the disclosure, shares fell 31.69% to $1.94, and the litigation remains in early procedural stages with no class certified.